2ND ANNUAL SCIENTIFIC MEETING OF THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

JOINT SPECIAL CONFERENCE WITH THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

Novel Approaches in Blood and Marrow Transplantation

October 2-6, 1996
Hotel del Coronado
San Diego, CA

CONFERENCE CO-CHAIRPERSONS

Bruce R. Blazar / Minneapolis, MN  O. Michael Colvin / Durham, NC

PROGRAM COMMITTEE

Karen S. H. Antman / New York, NY  Olivera J. Finn / Pittsburgh, PA
Joseph R. Bertino / New York, NY  Ronald E. Gress / Bethesda, MD
Barbara E. Bierer / Boston, MA  Helen E. Heslop / Memphis, TN
Richard E. Champlin / Houston, TX  John H. Kersey / Minneapolis, MN
Nelson J. Chao / Stanford, CA  Keith M. Sullivan / Seattle, WA
Connie J. Eaves / Vancouver, BC, Canada

PLENARY SESSIONS

Pharmacologic Approaches to Reducing Malignancy
Joseph R. Bertino / New York, NY
Robert B. Diasio / Birmingham, AL
William Hrynuiuk / San Diego, CA
O. Michael Colvin / Durham, NC

Biologic Approaches to Reducing Malignancy
Martin Kast / Chicago, IL
Fatih M. Uckun / Minneapolis, MN
John R. Murphy / Boston, MA
Glenn Dranoff / Boston, MA

Options for Hematopoietic Progenitor Cell Sources
Christopher Juttner / Palo Alto, CA
Peter M. Lansdorp / Vancouver, BC, Canada
Jan Nolta / Los Angeles, CA
Paul Martin / Seattle, WA

Allogeneic Approaches to Reducing Malignancy Post-BMT
Bruce R. Blazar / Minneapolis, MN
Ronald E. Gress / Bethesda, MD
Robert Kornfeld / Philadelphia, PA
Lee M. Nadler / Boston, MA

Biology of Breast Cancer
William P. Peters / Detroit, MI
Karen S. H. Antman / New York, NY
Jeffrey T. Holt / Nashville, TN
Daniel D. Von Hoff / San Antonio, TX

SCIENTIFIC SUBCOMMITTEES AND CHAIRPERSONS

Solid Tumors
Emil Frei III / Boston, MA
William P. Peters / Detroit, MI

Lymphoid Malignancies
Jerome Ritz / Boston, MA
Gordon L. Phillips / Lexington, KY

Experimental Therapeutics
O. Michael Colvin / Durham, NC
Stanley Riddell / Seattle, WA

Gene Therapy
Donald B. Kohn / Los Angeles, CA
Malcolm K. Brenner / Memphis, TN

Growth Factors and Sources of Stem Cells
Joanne Kurtzberg / Durham, NC
Malcolm A. S. Moore / New York, NY

Graft Rejection/GVHD/GVL
Els Goulmy / Leiden, The Netherlands
Martin A. Cheever / Seattle, WA

Supportive Care
John R. Wingard / Atlanta, GA
Raleigh Bowden / Seattle, WA

Leukemias
Edward D. Ball / Pittsburgh, PA
Michael L. Cleary / Stanford, CA

Non-malignant Disorders:
Congenital and Acquired
Robertson M. Parkman / Los Angeles, CA
Rainer F. Storb / Seattle, WA

Abstract Deadline: July 15, 1996

Information and Registration Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 / 215-440-9313 (FAX)
e-mail: aacr@aol.com
CELL SIGNALING AND CANCER TREATMENT

An American Association for Cancer Research Special Conference
in Collaboration with
Austrian Cancer Society, British Association for Cancer Research,
German Cancer Society and the Austrian Biochemical Society

February 23-28, 1997
Interalpen-Hotel Tyrol
Telfs-Buchen, Austria

CONFERENCE CHAIRPERSONS
Hans H. Grunicke / Innsbruck, Austria
Garth Powis / Tucson, USA
Paul Workman / Macclesfield, England

PROGRAM COMMITTEE

Sara A. Courtneidge / Redwood City, USA
Sylvie Gisselbrecht / Paris, France
Bernd Groner / Freiburg, Germany
Adrian L. Harris / Oxford, England
Peter A. Herrlich / Karlsruhe, Germany

Peter Hilgard / Frankfurt, Germany
Alex Matter / Basel, Switzerland
Frank P. McCormick / Richmond, USA
Laurent Meijer / Roscoff, France
Michael J. Morin / Groton, USA

Axel Ullrich / Munich, Germany

Keynote Address
Paul Workman / Macclesfield, England

Growth Factor Antagonists and Growth Factor Receptor Blockers

Enrique Rozengurt / London, England
Nancy E. Hynes / Basel, Switzerland
Bernd Groner / Freiburg, Germany
Nicholas Lydon / Basel, Switzerland

Receptor and Post Receptor Signaling: Mechanisms and Targets in Cancer Chemotherapy

Sara A. Courtneidge / Redwood City, USA
Frank P. McCormick / Richmond, USA
Nicholas K. Tonks / Cold Spring Harbor, USA
Garth Powis / Tucson, USA
Ulf R. Rapp / Würzburg, Germany
Alan K. Hall / London, England
Axel Ullrich / Munich, Germany

Cell Cycle and Cancer
Laurent Meijer / Roscoff, France
Christian Brechot / Paris, France
Rolf Müller / Marburg, Germany
J. Wade Harper / Houston, USA

Cytokine Signaling
Sylvie Gisselbrecht / Paris, France
Atsushi Mihayama / Tokyo, Japan
Ian M. Kerr / London, England
Gennaro Ciliberto / Rome, Italy

Programmed Cell Death: Role in Oncogenesis and Tumor Therapy

Gerard L. Evan / London, England
Caroline Dive / Manchester, England
Douglas R. Green / La Jolla, USA
Donald W. Nicholson / Pointe-Claire-Dorval, Quebec, Canada

Invasion and Metastasis

Max M. Burger / Basel, Switzerland
Louis F. Reichardt / San Francisco, USA
John G. Collard / Amsterdam, The Netherlands
Helmut Porta / Karlsruhe, Germany

Angiogenesis
Adrian L. Harris / Oxford, England
Kari K. Alitalo / Helsinki, Finland
Isaiah J. Fidler / Houston, USA

Applications are encouraged to submit abstracts for poster presentation.

Application deadline: November 1, 1996

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aol.com
Arthur W. Nienhuis (top left) has been Director of St. Jude Children’s Research Hospital in Memphis, TN, since 1993. Throughout his distinguished career, Dr. Nienhuis’ research has focused on attempts to understand the molecular mechanisms of hematological diseases. He contributed to the elucidation of the molecular basis of thalassemia and to the understanding of the regulation of fetal hemoglobin synthesis and its manipulation for therapeutic benefit. His current research is targeted toward the development of gene therapy for blood diseases by gene insertion into hematopoietic stem cells.

Dr. Nienhuis received his M.D. from the School of Medicine of the University of California at Los Angeles in 1968. He served his internship and residency at Massachusetts General Hospital in Boston, MA, followed by clinical fellowships at Harvard Medical School in Cambridge and Children’s Hospital Medical Center in Boston. He moved on to the NIH’s National Heart, Lung and Blood Institute (NHLBI) in Bethesda, MD, in 1973, where he participated in early gene manipulation work. He became Chief of the NHLBI’s Clinical Hematology Branch in 1977, which position he held prior to his arrival at St. Jude Hospital. He has authored 200 original articles and 75 chapters, reviews, and editorials, in addition to editing 10 books. He also served as Editor of Blood from 1988–92. Among his scientific honors are his receipt of the Public Health Service Meritorious Service Medal in 1990 and his election as President of the American Society of Hematology in 1994. He is an active member of the American Association for Cancer Research, currently serving on the Clinical Investigations Subcommittee of the 1997 Annual Meeting Program Committee.

In accordance with St. Jude Hospital’s mission of providing unsurpassed patient care that depends on research to understand the causes, to improve treatment, and to effect cures of the catastrophic illnesses of childhood, Dr. Nienhuis has broadened the strategic vision of the Hospital. As insights provided by cellular and molecular biology have created new opportunities to help improve the health of children through biomedical research, St. Jude Hospital has expanded its research on the genetic therapy of cancer and inherited genetic diseases as well as its efforts in translational research, an area dedicated to bringing advances in the laboratory to clinical application. Also in keeping with the Hospital’s objectives, a Department of Structural Biology is being formed to attract top scientists with established research strengths. Such has already been the case with the Hospital’s Department of Developmental Neurobiology, which opened in September 1995. Senior research scientists from the Roche Institute of Molecular Biology in New Jersey transferred to St. Jude Hospital where their research now focuses on the molecular basis of brain development. This work complements the Hospital’s radiation oncology efforts to identify new treatments for brain tumors and other neurological problems. St. Jude Hospital recently began to employ gene transfer for pediatric brain tumor patients, treatment that has shown some signs of effectiveness in adult brain patients at other centers.

The Hospital’s recently opened Patient Care Center (bottom) is both a showcase of patient care efficiency and a facility for the implementation of new research directions. It houses St. Jude Hospital’s Transplantation and Gene Therapy Program, which includes a 10-bed unit that provides a clinical setting where specialized staff can address the unique needs of children undergoing transplantation or a gene therapy procedure. Adjacent to this clinical unit are laboratories that process human cells used for therapeutic purposes, including gene transfer procedures. The work in these laboratories is focused on employing what has been learned in research laboratories regarding cell or gene manipulation and on applying that knowledge directly to patient care. The physical proximity of the Clinical Transplantation Unit and the Cell and Gene Therapy Laboratories fosters an integrated effort to improve patient care. The facility offers the opportunity for St. Jude Hospital to take a leading national role in both transplant and gene therapy programs. While a few other centers are developing similar facilities or already have them in operation, the unique focus at St. Jude Hospital is on the catastrophic illnesses of childhood.

The Patient Care Center adjoins the Danny Thomas Research Tower (top right), which was named for the late entertainer who founded, directed, and supported the institution until his death in 1991. The Research Tower is home to the Departments of Genetics, Biochemistry, Tumor Cell Biology, Experimental Oncology, Immunology, Virology/Molecular Biology, Molecular Pharmacology, Developmental Neurobiology, Pathology Research, Pharmaceutical Sciences, and Hematology/Oncology’s Divisions of Experimental Hematology and Bone Marrow Transplantation. Designed with participation from the basic science staff, the Tower provides maximum flexibility for the staff to research congenital and inherited disorders in addition to the pediatric tumors and leukemias for which the Hospital is renowned.

To complete the current expansion program at St. Jude Hospital, the American Lebanese Syrian Associated Charities (ALSAC), headquartered in Memphis, has funded the $140 million renovation of the ALSAC Tower, which had opened originally in 1975. It has been expanded to make room for two new vector production laboratories for the gene therapy program and to house the Departments of Infectious Diseases, Pathology and Laboratory Medicine, and Molecular Pharmacology.

We extend our thanks to Mr. Jerry Chipman, Director of Public Relations at St. Jude Hospital, for his assistance in the coordination of the material for this legend.

Sidney Weinhouse